Austin, Rebecca J.
Straube, Jasmin http://orcid.org/0000-0002-1748-0659
Halder, Rohit
Janardhanan, Yashaswini
Bruedigam, Claudia
Witkowski, Matthew http://orcid.org/0000-0003-1434-4288
Cooper, Leanne
Porter, Amy
Braun, Matthias
Souza-Fonseca-Guimaraes, Fernando
Minnie, Simone A.
Cooper, Emily
Jacquelin, Sebastien
Song, Axia
Bald, Tobias
Nakamura, Kyohei http://orcid.org/0000-0002-6631-9028
Hill, Geoffrey R.
Aifantis, Iannis
Lane, Steven W. http://orcid.org/0000-0002-8050-6209
Bywater, Megan J. http://orcid.org/0000-0002-7466-6927
Funding for this research was provided by:
Department of Health | National Health and Medical Research Council (1088703, 2003575)
Leukaemia Foundation
CSL Centenary Fellowship (SWL), Herron Family Trust, Gordon and Jessie Gilmour
Article History
Received: 12 October 2021
Accepted: 22 March 2023
First Online: 14 April 2023
Competing interests
: S.W.L. has participated in advisory boards for Celgene, Novartis and Janssen, and has received research funding from Janssen and Celgene/ Bristol Myers Squibb for unrelated projects. G.R.H. has consulted for Generon Corporation, NapaJen Pharma, iTeos Therapeutics, Neoleukin Therapeutics and has received research funding from Compass Therapeutics, Syndax Pharmaceuticals, Applied Molecular Transport, Serplus Technology, Heat Biologics, Laevoroc Oncology, Genentech and iTeos Therapeutics. F.S.F.G. is a consultant and has a funded research agreement with Biotheus Inc. The remaining authors declare no other competing interests.